ClinicalTrials.gg
RecruitingNCT07556913Updated Oct 23, 2026

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

An observational study in Pregnancy Related, sponsored by Ipsen. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ipsen · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 6, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3
Sex
Female
01

Study summary

The study will include participants who were exposed to at least one dose of elafibranor either within the three weeks before conception or at any time during pregnancy (based on estimated last menstrual period [LMP]).

Information will be collected from participants, their healthcare providers, published studies, and safety databases. Reports of pregnancy linked to elafibranor from clinical trials, spontaneous reports, or literature will also be included, with steps taken to avoid duplicates.

The study begins once the first participant is enrolled and ends after the last mother and child data are collected. It is planned to run for about 10 years, with infant follow-up lasting up to 2 years, for a maximum total duration of 12 years and 9 months.

The program is strictly observational. All medical care, visit schedules, and treatment decisions remain with healthcare providers. Only routine medical record data will be collected, and no extra tests or procedures are required.

Participation is voluntary, and written informed consent will be obtained before enrollment.

02

Conditions studied

  • Pregnancy Related

Keywords

  • Rare disease
  • Primary Biliary Cholangitis
  • Pregnancy
03

In context

Rare Diseases

592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.

This study's planned enrollment of 3 is below the median of 133 across 208 observational studies indexed under Rare Diseases.

Browse Rare Diseases studies →

Lead sponsor

Ipsen is the lead sponsor of 291 studies on the registry; 19 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

The participants of this study will be of any age who are exposed to at least one dose of elafibranor at any time during pregnancy, or since 3 weeks prior to the conception (based on estimated last menstrual period [LMP])

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maternal exposure to at least one dose of elafibranor, either: Within three weeks prior to conception (based on the estimated date of LMP) or At any time during pregnancy (from the estimated date of conception through pregnancy outcome).
  • Participants who were previously enrolled in this program during a past pregnancy and who meet inclusion criteria #1 for the subsequent pregnancy are eligible to enroll again.
  • or IRB/IEC-approved waiver of informed consent (not applicable if reported by Ipsen PV according to usual pharmacovigilance practices).

Exclusion criteria

Exclusion Criteria:

  • Participant with mental instability or incompetence, such that the validity of or ability to be compliant with the study is uncertain.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3 participants (estimated)
Target follow-up
33 Months
Patient registry
Yes

Groups and cohorts

  • Elafibranor Cohort

    Participants who are exposed to at least 1 dose of elafibranor at any time during pregnancy and/or lactation

    Drug: Elafibranor

Interventions

  • DrugElifibranorStudies of ElifibranorElifibranor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The medicinal product elafibranor is prescribed in the usual manner in accordance with the terms of the marketing authorization of the participants' country.

06

What researchers measure

Primary outcomes

  1. Prevalence of congenital malformations at birth

    Time frame: At birth

Secondary outcomes

  1. Prevalence of major congenital malformations at birth

    An abnormality of body structure or function that is present at birth; is of prenatal origin (i.e. birth defect); has significant medical, social, or cosmetic consequences for the affected individual; and typically requires medical intervention

    Time frame: At birth

  2. Prevalence of minor congenital malformations at birth

    An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e. birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual

    Time frame: At birth

  3. Prevalence of molar/ectopic pregnancy

    Molar pregnancy is defined as an abnormal pregnancy that happens when a sperm fertilizes an egg that does not contain any genetic material. Ectopic pregnancy is defined as a pregnancy that occurs outside of the uterine cavity, usually in one of the fallopian tubes.

    Time frame: Throughout pregnancy, an average of 9 months

  4. Prevalence of fetal loss

    A fetal loss that occurs for any reason at any time during pregnancy. This includes spontaneous abortion (SAB), stillbirth, elective or therapeutic abortion, fetal loss (type not specified).

    Time frame: Throughout pregnancy, an average of 9 months

  5. Prevalence of live birth

    The birth of a living fetus at ≥ 20 gestational weeks or, if gestational age is unknown, weighing ≥ 350g.

    Time frame: At birth

  6. Prevalence rate of premature delivery

    A live birth occurring at \<37 gestational weeks.

    Time frame: At birth

  7. Prevalence of infants born small for gestational age (SGA) at birth

    Birth weight \<10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants.

    Time frame: At birth

  8. Prevalence of neonatal death

    Time frame: Within the first 28 days of life

  9. Prevalence infant death

    Time frame: Throughout the first year of life

  10. Prevalence of postnatal growth deficiency

    Weight, length, or head circumference in \<10th percentile for sex and age using standard growth charts

    Time frame: Throughout the two years of life

  11. Prevalence of infant developmental delay

    Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention (CDC)

    Time frame: Throughout the two years of life

  12. Prevalence of infant healthcare requirements and interventions not considered standard

    including but not limited to: * Infant hospitalization due to serious illness * Emergency department visits * Specialist or other healthcare professional consultations * Developmental assessments and interventions * Therapeutic services * Educational support and adaptations

    Time frame: Throughout the two years of life

  13. Incidence and nature of all adverse events in pregnant participants

    Time frame: Throughout pregnancy, an average of 9 months

  14. Changes from baseline in Alkaline phosphatase (ALP)

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  15. Changes from baseline in Bilirubin

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  16. Changes from baseline in Alanine aminotransferase (ALT)

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  17. Changes from baseline in Aspartate aminotransferase (AST)

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  18. Changes from baseline in Gamma-glutamyl transferase (GGT)

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  19. Changes from baseline in Albumin

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  20. Changes from baselinein Bile Acids

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  21. Changes from baseline in Creatine phosphokinase (CPK)

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

  22. Changes from baseline in Lipid Profile

    Lipid profile includes total cholesterol, low density lipoproteins (LDL-C), high density lipoprotein (HDL-C), very low density lipoprotein and triglycerides

    Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months

07

Study locations

1 of 1 sites recruiting
  • Virtual Research Coordination Center
    Wilmington, North Carolina 28401, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2039, 150 months after the start.

Of 88 observational studies under Rare Diseases, half reached primary completion within 118 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 183. This study's planned 150 months is above that.

Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Jan 31, 2039
CompletionEst.
Jan 31, 2039
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Arms or interventions changed
Oct 6, 2026
Show all 2 updates
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 6, 2026
    Interventions Arms or interventions changed
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07556913
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jul 29, 2026
Primary completion
Jan 31, 2039 (estimated)
Completion
Jan 31, 2039 (estimated)
Last update
Oct 23, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
See e-mail
Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion